HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warner Chilcott PLC

http://www.wcrx.com/index.jsp

Latest From Warner Chilcott PLC

Examining The Antibody-Drug Conjugate Pipeline

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches. 

Clinical Trials Growth

Avidity Is The Mid-Cap Rising Star Of 2024 So Far

New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.

Commercial Companies

Accelerated Approval: ALS Drug Could Test New Congressional Directive On Survival

Clene leadership spoke with the Pink Sheet about its push for accelerated approval for its ALS nanoparticle treatment. A new nudge from Congress asking the US FDA to consider survival data in accelerated approval could help.

Drug Approval Standards FDA

The Prospects For Earlier-Stage Antibody-Drug Conjugates

Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.

Clinical Trials Commercial
See All

Company Information

  • Other Names / Subsidiaries
    • Galen Holdings PLC
UsernamePublicRestriction

Register